Abstract Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. Logistic regression generated odds ratios (OR) and 95 % confidence intervals (CI) for the associations of race, ethnicity, and BMI with in-breast pCR adjusting for subtype, study arm, lymph node status, tumor size, and tumor grade. 253 (14.1 %) were black, 199 (11.1 %) Hispanic, 520 (28.9 %) overweight, and 743 (41.4 %) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor subtype. In multivariate analyses, neither race (black vs white: OR 1.18, 95 % CI 0.85-1.62) nor ethnicity (Hispanic vs non-Hispanic; OR 1.30, 95 % CI 0.67-2.53) were significant predictors of pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER?/HER2?, but higher pCR rates in ER-/HER2? cancers. There was no difference in pCR according to race or ethnicity. Overall, there was no major difference in pCR rates by BMI. These findings suggest that pCR with optimally dosed NST is a function of tumor, rather than patient, biology.
Introduction
Obesity [1, 2] and black race [3, 4] have each been independently associated with poor breast cancer outcomes. The relationship of Hispanic ethnicity with breast cancer outcomes has been inconsistent with some studies suggesting equal or superior outcomes when compared to nonHispanic whites, while others suggest worse outcomes [3, 5, 6] . Black race, Hispanic ethnicity, and obesity are each associated with a higher incidence of more aggressive tumor biology (high grade, hormone receptor negative, high proliferation fraction, more lymphovascular invasion) & Erica T. Warner ewarner@mgh.harvard.edu [5, 7, 8] . Differences in tumor subtype likely contribute to observed poorer outcomes, but residual disparities remain [9] . This could be due, at least in part, to differences in response to therapy [10] . In addition, differences in quality of chemotherapy, including treatment delays [11, 12] and suboptimal dosing [13] , may contribute to disparate breast cancer outcomes according to race, ethnicity, and body mass index (BMI). Given the high prevalence of overweight and obesity among black and Hispanic women in the US, it is possible that race and BMI may interact. In an effort to address these disparities, it is important to investigate whether, independent of their measurable tumor characteristics, and in a setting of standardized therapeutic regimens, overweight, obesity, or black race are associated with response to therapy. Achievement of a pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) can be defined in a number of ways, but all definitions include the absence of residual invasive cancer in the breast (in-breast pCR). Some definitions also require the absence of invasive and in situ disease, and include the axillary nodes [14] . While the absence of invasive and in situ disease in the breast and the axillary nodes is most strongly associated with favorable prognosis [15] , in-breast pCR is highly correlated with pCR in the axillary nodes [16] . Regardless of definition, pCR rates differ greatly across tumor subtypes with the highest rates observed among patients with triple-negative or estrogen receptor (ER)-negative, human epidermal growth factor receptor-2 (HER2)-positive (ER-/HER2?) cancers, while very low pCR rates are seen in patients with ER?/HER2-tumors [17] . In an era of personalized medicine, NST often allows women with locally advanced breast cancer to become candidates for breast conserving surgery [18] and permits in vivo assessment of treatment response [19] . Women achieving pCR have better eventfree and overall survival than those who do not, though this association is also subtype dependent [15] . The greatest survival benefits of pCR appear to occur in patients with triple-negative and ER-/HER2? tumors [20] . Because of its demonstrated association with survival, the Food and Drug Administration allows pCR to be used as a surrogate endpoint for accelerated approval in pharmaceutical trials [21] .
Given the observed disparities in survival according to race, ethnicity, and BMI and the association of pCR with survival, the purpose of this study was to examine the association of race, ethnicity, and BMI with pCR in clinical trial populations. Our sample includes multiple trials in which chemotherapy dosing, which may vary considerably between patient populations outside of trials [22, 23] , was standardized and rigorously accounted for. Using data of 1797 women participating in four Alliance for Clinical Trials in Oncology (Alliance) clinical trials, we evaluated the proportion of women achieving in-breast pCR according to race, ethnicity, and BMI. We examined these factors overall and stratified by subtypes defined by ER status and HER2.
Methods

Study population
This analysis pools data from four neoadjuvant chemotherapy clinical trials conducted by the members of the Alliance (Table 1) , Cancer and Leukemia Group B (CALGB) and American College of Surgeons Oncology Group (ACOSOG) who are now part of the Alliance. Two trials (CALGB 40601 and ACOSOG Z1041) were limited to patients with HER2? cancers, while one (CALGB 40603) enrolled only patients with triple-negative cancers [24] [25] [26] . The fourth trial (ACOSOG Z1071) included all breast cancer subtypes of breast cancer; it was designed to evaluate the false-negative rate for sentinel lymph node surgery following neoadjuvant chemotherapy in women initially presenting with biopsy-proven node-positive breast cancer [27] . All trials were approved by the appropriate medical ethics committees. All patients gave written informed consent for study participation and data collection.
Data collection and statistical analysis
Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center. Race and ethnicity were self-reported, and BMI was collected by institutional study coordinators from chemotherapy orders. Breast cancer tumor subtypes were assigned on the basis of clinical ER and HER2 status as determined locally. ER was assessed by standard criteria using immunohistochemical (IHC) staining. HER2 was assessed using either IHC or fluorescence in situ hybridization (FISH). Pathologic complete response was defined as the absence of residual invasive disease in the breast (ypT0/is). This was the primary endpoint for all trials except Z1071, which as noted previously, evaluated a nodal question but collected breast and nodal pCR rates on participants.
Analyses included 1797 women from the four trials. We used logistic regression models to examine the relationship between race, ethnicity BMI, and response to neoadjuvant chemotherapy. We evaluated the association between race (Black or White), ethnicity (Hispanic or Non-Hispanic), and BMI (\20, 20-24, 25-29, C30 kg/m 2 ) with pCR in the breast following NST. We tested for potential interaction between race and BMI using a cross product term. We present models overall and stratify by subtypes defined by ER status and HER2 (ER?/HER2-, ER?/HER2?, ER-/ HER2?, and triple negative). Models are adjusted for subtype (overall model only), study arm, lymph node status, and tumor grade. Tumor size was not collected in Z1041. We performed a sensitivity analysis by running models with and without tumor size included (using a missing indicator). As results did not materially differ, we present results without adjustment for tumor size. Statistical tests were two-sided, and p \ 0.05 was considered significant. Statistical analyses were performed by Alliance statisticians at the Alliance Statistics and Data Center using SAS version 9.3 (SAS Institute, Cary, NC) on a dataset frozen on January 13, 2016. (Table 2) Of the 1797 women included in analyses, 1177 (83.1 %) were white, 253 (14.1 %) were black, 127 (7.1 %) were listed as 'other', 199 (11.1 %) were Hispanic, and 520 (28.9 %) were overweight (BMI [25] [26] [27] [28] [29] and 743 (41.3 %) were obese (BMI C 30 kg/m 2 ). Information on ER, PR, and HER2 status was available for 1784 (99.3 %) patients. The mean age of overweight and obese women (50.5 years) was higher than for normal weight women (47.4 years) (p \ 0.0001). Compared to white women, a higher percentage of black women had triple-negative cancers (49.8 vs 34.1 %), with consequent reductions in the percentage of black women with ER? and HER2? cancers (p = 0.0001). A slightly higher percentage of black women had clinically node-positive disease at study entry (24.9 vs 18.8 % for white women; p = 0.05). Compared to white women, black women had a higher mean BMI (31.9 vs 29.1 kg/m 2 ; p \ 0.0001) and were more likely to be obese (60.1 vs 38.9 %; p \ 0.0001). Hispanic women were also more likely to be obese than non-Hispanic women (49.2 vs 41.2 %; p = 0.0003). Aside from a slight increase in the percentage of patients with triple-negative cancers who were obese (43.8 vs 40.2 % for other subtypes), there were no major differences in the distribution of BMI among the subtypes (p = 0.68).
Results
Patient Characteristics
pCR rates, race, and ethnicity (Tables 3, 4 achieved pCR as compared to 39.8 % (550/1381) of white women. Adjusting for subtype and other potential confounders, we observed no significant association between black race and pCR (OR 1.18, 95 % CI 0.85-1.62). In analyses stratified by tumor subtype, we also saw no significant differences in pCR rates between black and white women (Table 4) . Hispanic ethnicity was also not associated with pCR, either overall (Table 3) or when stratified by tumor subtype (Table 4) . Overall, 46.4 % (90/194) of Hispanic women achieved pCR compared to 39.6 % (570/ 1441) of non-Hispanic women. Adjusting for subtype and other potential confounders, we found no significant association between Hispanic ethnicity and pCR (OR 1.22, 95 % CI 0.86-1.72). In analyses stratified by tumor subtype, we also saw no significant differences in pCR rates between Hispanic and non-Hispanic women (Table 4) .
BMI and pCR (Tables 3, 4)
Compared to normal weight women (BMI 20-24), in whom the overall pCR rate was 43.6 %, the small cohort (n = 66, 3. 
Discussion
In this large pooled analysis of four randomized clinical trials including 1797 patients, we examined whether race, Hispanic ethnicity, and/or BMI were associated with inbreast pathologic complete response to neoadjuvant chemotherapy and HER2-targeted therapy in patients with HER2? cancers. We observed no difference in pCR rates according to race or ethnicity overall or when stratified by tumor subtype. We observed no overall differences according to BMI, but did see trends associating increasing BMI with lower pCR rates in ER?/HER2? patients and higher pCR rates in ER-/HER2? patients. In our study, pCR rates were similar in black and white women as well as in Hispanics and non-Hispanics. Several previous studies have examined the association between race and pCR with some finding no difference by race [10, 28] , while others found lower pCR rates among black women [29, 30] . Chavez-MacGregor and colleagues found no differences in pCR rates between blacks, whites, and Hispanics, overall or within tumor subtypes, in a retrospective analysis of 2074 patients treated at the M.D. Anderson Cancer Center between 1994 and 2008, in which the reported pCR rates (overall = 12.5 %, HER2? 22.6 %, triple negative 19.4 %, hormone receptor-positive 5 %) were much lower than in our population. 28 These lower observed pCR rates are at least in part because of differences in pCR definition (in-breast vs. breast and axilla) and use of combination therapy (i.e., trastuzumab) in our trials. In a more recent paper, Killelea and colleagues, using data from the National Cancer Data Base (NCDB), found similar pCR rates across racial groups [29] . There were no significant differences according to Hispanic ethnicity. The different results in the present study and that by Killelea et al. may be due to our use of clinical trial populations. The setting of randomized clinical trials provides several important advantages including standardized enrollment requirements, uniform assessment of disease characteristics such as stage, tumor phenotype, and other factors associated with prognosis. Treatment is also standardized, carefully monitored, and facilitated, eliminating variation in care that may occur outside of a trial. While the NST regimen for patients enrolled on Z1071 was not specified in the protocol, most received an anthracycline and a taxane in the neoadjuvant setting, and since the treating physicians at the participating institutions were familiar with treatment guidelines from other cooperative group trials, we considered it highly likely that the treatment plans utilized followed similar guidelines (standard chemotherapy dosing using actual rather than ideal body weight to calculate body surface area, for example). Though most of the available data are from the adjuvant setting, there is evidence that black women with earlystage breast cancer start chemotherapy later, are more likely to receive a lower than standard dose and lower relative dose intensity, and are more likely to have dose reductions in the first and subsequent treatment cycles compared to whites [31, 32] . These differences could not be explained by racial differences in BMI, comorbid conditions, or hematological factors [33] . There is also little evidence of greater levels of acute toxicity in black women receiving neoadjuvant or adjuvant chemotherapy [34] . It is possible that the lower pCR rates among black women in the NCDB are due to dose reductions, treatment delays, or differences in chemotherapy regimens received. Taken together, our results suggest that racial differences in pCR identified in retrospective studies may not be caused by biology.
Our results suggest that, overall, in-breast pCR rates are not significantly affected by BMI in appropriately dosed patients, though there was a nonsignificant trend toward lower pCR rates with a higher BMI (p-trend = 0.094). In another retrospective analysis from the M. D. Anderson database, Litton and colleagues found that overweight (OR 0.59, 95 % CI 0.37-0.95) or the combination of overweight and obese (OR 0.67, 95 % CI 0.45-0.99) women had significantly lower pCR rates compared to normal/underweight women. 35 Results were not stratified by tumor subtype [35] . Among Chinese women, patients with BMI C 25 kg/m 2 were 55 % less likely to achieve pCR compared to those with BMI \ 25 kg/m 2 . Differences were the largest among postmenopausal and HR-patients [36] . Several other studies have associated lower BMI with higher rates of pCR [37] . Weight gain during neoadjuvant chemotherapy has not been associated with pCR [38] , except perhaps in subgroups of women who were normal/ underweight or postmenopausal at baseline, where it was associated with higher pCR rates [39] .
In our study, the impact of BMI on pCR appeared to differ by tumor subtype. Specifically, in overweight and obese women, we saw lower pCR rates in ER?/HER2? cancers and higher pCR rates in ER-/HER2? cancers. However, confidence intervals were wide and it is possible that result was due to chance. Potential mechanisms relating overweight and obesity to lower pCR rates and poorer survival include (1) higher circulating estrogen levels among obese postmenopausal women as compared to leaner women and higher estrogen levels when on aromatase inhibitor therapy [40] , (2) higher levels of circulating insulin, adiponectin, C-peptide, leptin, and other metabolic hormones [41] , and (3) higher circulating inflammatory cytokines which may reduce apoptosis and increase proliferation among obese women [42, 43] . In some settings, chemotherapy may not be dosed appropriately leading to underdosing of obese women, and this would have a greater impact on black women where we observed higher rates of obesity compared to whites [44, 45] . Chemotherapy underdosing is less of a concern in our clinical trials because weight-based dosing is required [24] [25] [26] .
Our study has several important strengths and limitations. While our analysis included almost 1800 women, dividing the population by tumor subtype, race, ethnicity, and BMI limited our statistical power. Our outcome was in-breast pCR (ypT0/Tis), while many other studies have used pCR in the breast and axillary nodes (ypT0/Tis ypN0) pCR as their endpoint, as it has a stronger association with disease-free survival [20, 46] . However, in order to explain the difference in results between our study and those using ypT0/Tis ypN0, race or BMI would have to only affect the likelihood of achieving pCR in the axilla, but not in the breast. This seems unlikely since most women who achieve in-breast pCR also do so in the axilla [15] . Assigning subtype by ER and HER status alone ignores certain molecular heterogeneity within those subtypes that may impact tumor response and achievement of pCR [47, 48] . While the treatment regimens received across our included trials were not uniform, within each trial with the exception of Z1071, patients received standardized therapy. Clinical trial participants may not be representative of the general population. For example, clinical trial participants are generally younger than patients in the community [49] . Lack of racial and ethnic diversity is problematic in many clinical trials; however, our sample was 14 % black and 11 % Hispanic, reasonably similar to their distribution in the United States. Lastly, we did not look at long-term outcomes associated with pCR according to race, ethnicity, or BMI. Trials suggest that among women who achieve pCR, outcomes such as disease-free survival and overall survival are similar, but disparities persist among women who do not [28, 50] . Further research is necessary to tease apart molecular characteristics, post-neoadjuvant treatment, and behavioral/environmental exposures that contribute to these disparities among nonresponders.
In conclusion, our study found no differences in breast pCR according to race or Hispanic ethnicity and no significant impact of BMI on the overall pCR rate. These findings suggest that achievement of pCR with optimally dosed NST is largely a function of tumor, rather than patient, biology. It further suggests that yet-to-be-defined biologic factors that may influence which patients within each subtype achieve a pCR are also little influenced by race, ethnicity, and BMI; if these patient characteristics determined those factors, we would expect to see more substantial differences in the pCR rates among our subgroups. Analysis of other studies utilizing similarly effective NST regimens are warranted to see, if they also demonstrate lower pCR rates in ER?/HER2? and higher pCR rate in ER-/HER2? overweight and obese women who could generate hypotheses for the etiology of these observations.
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